Form 4: Gossamer Bio Director Acquires 230,000 Stock Options
SEC Form 4 Filing
Director Steven D. Nathan acquired 230,000 stock options in Gossamer Bio, Inc. on March 11, 2024.
Summary
- On March 11, 2024, Steven D. Nathan, a director of Gossamer Bio, Inc., acquired 230,000 stock options.
- The exercise price of these options is $1.34.
- The options vest monthly over three years, contingent upon continuous service to the corporation.
- The options expire on March 10, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option grants, which is neutral in sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of transaction: Director Steven D. Nathan acquired 230,000 stock options. |
| 03/12/2024 | Date of signature by Attorney-in-Fact. |
| 03/10/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.